Meridian Bioscience, Inc. (VIVO)

NASDAQ: VIVO · IEX Real-Time Price · USD
20.67
-0.08 (-0.39%)
Jan 27, 2022 3:59 PM EST - Market open

Company Description

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.

The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood.

It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.

The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications.

Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Meridian Bioscience, Inc.
Meridian Bioscience Logo
CountryUnited States
IndustryHealth Care Equipment & Supplies
SectorHealth Care
Employees702
CEOJohn Kenny

Contact Details

Address:
3471 River Hills Dr
Cincinnati, Ohio 45244-3023
United States
Phone513 271 3700
Websitemeridianbioscience.com

Stock Details

Ticker SymbolVIVO
ExchangeNASDAQ
Fiscal YearOctober - September
Reporting CurrencyUS Dollars
CIK Code0000794172

Key Executives

NamePosition
John P. KennyPresident, Chief Executive Officer and Director
Dr. Lourdes G. Weltzien Ph.D.Executive Vice President of Life Science Business Unit
Tony Serafini-LamannaExecutive Vice President of Diagnostics
Julie SmithSenior Vice President, Controller and Principal Accounting Officer
Jeff PinkstonDirector of Corporate Finance
Charles WoodVice President of Corporate Strategy, Business Development and Investor Relations
Melissa J. McCareyVice President of Global Human Resources
Susan D. RolihConsultant
Melissa A. LuekeConsultant

Latest SEC Filings

DateTypeTitle
Jan 14, 20224Statement of changes in beneficial ownership of securities
Jan 3, 20223Initial statement of beneficial ownership of securities
Dec 22, 20214Statement of changes in beneficial ownership of securities
Dec 22, 20214Statement of changes in beneficial ownership of securities
Dec 16, 20214Statement of changes in beneficial ownership of securities
Dec 16, 20214Statement of changes in beneficial ownership of securities
Dec 16, 20214Statement of changes in beneficial ownership of securities
Dec 15, 2021DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 15, 2021DEF 14AOther definitive proxy statements
Dec 2, 20218-KCurrent report
View All SEC Filings